Cellectar Biosciences Inc Stock price Nasdaq
Equities
US15117F3029
Pharmaceuticals
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 44.27M | Capitalization | 121M |
---|---|---|---|---|---|
Net income 2024 * | -49M | Net income 2025 * | -22M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.74 x |
P/E ratio 2024 * |
-2.44
x | P/E ratio 2025 * |
-6.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.48% |
Latest transcript on Cellectar Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
James V. Caruso
CEO | Chief Executive Officer | 65 | 15-06-14 |
Chad J. Kolean
DFI | Director of Finance/CFO | 59 | 14-05-27 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 23-02-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 73 | 17-04-06 |
Douglas Swirsky
CHM | Chairman | 54 | 17-04-06 |
John Neis
BRD | Director/Board Member | 68 | 08-01-31 |
1st Jan change | Capi. | |
---|---|---|
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |